Can nintedanib be taken with hormones?

Nintedanib (Nintedanib) is an oral multi-target tyrosine kinase inhibitor, mainly used to treat idiopathic pulmonary fibrosis and interstitial lung disease, or non-small cell lung cancer. There is no absolutely clear clinical conclusion regarding the combined use of nintedanib and hormones (such as corticosteroids), which mainly depends on the patient's specific condition, treatment goals, and the doctor's clinical judgment.

The main mechanism of action of nintedanib is by inhibiting several key growth factor receptors, including platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR) and epidermal growth factor receptor (EGFR), thereby reducing fibrosis and tumor growth. And hormones, especially corticosteroids, are often used to reduce inflammatory responses and modulate the immune system. The differences in the mechanisms of action between the two require careful evaluation when used together.

In some cases, doctors may choose to combine nintedanib with hormones, especially in those with comorbid inflammatory or autoimmune conditions. Hormones can help control these inflammatory responses, while nintedanib can target underlying fibrotic or neoplastic lesions. However, taking these medications together may also increase the risk of side effects. For example, common adverse reactions of nintedanib include gastrointestinal discomfort, abnormal liver function and cardiovascular problems, while long-term use of hormones may lead to immunosuppression, hyperglycemia, osteoporosis, etc. Therefore, when considering combination therapy, the potential benefits must be weighed against the risks.

In clinical practice, doctors often formulate treatment plans based on the patient's individual conditions. If a significant inflammatory response occurs while a patient is being treated with nintedanib, doctors may evaluate the need to introduce hormonal therapy. At the same time, when using hormones, it is also necessary to monitor their impact on the efficacy of nintedanib and whether it will aggravate the adverse reactions of nintedanib.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/ofev